• J&J, Legend's CAR-T therapy cilta-cel granted priority review by FDA firstwordpharma
    May 27, 2021
    The FDA has accepted a marketing application for Johnson & Johnson and partner Legend Biotech's BCMA-directed CAR-T therapy ciltacabtagene autoleucel (cilta-cel) for priority review as a potential treatment of adults with relapsed and/or refractory
PharmaSources Customer Service